Pure Global

Integrated Intravascular Ultrasound and Near-Infrared Spectroscopy (IVUS + NIRS) - Vietnam Registration 240000757/PCBB-HCM

Access comprehensive regulatory information for Integrated Intravascular Ultrasound and Near-Infrared Spectroscopy (IVUS + NIRS) in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TTBYT Loại B medical device is registered under number 240000757/PCBB-HCM and manufactured by Infraredx, Inc.. The authorized representative in Vietnam is CÔNG TY TNHH NIPRO SALES VIỆT NAM.

This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.

Free Database
Powered by Pure Global AI
300,000+ Devices
240000757/PCBB-HCM
Registration Details
Vietnam MOH Registration: 240000757/PCBB-HCM
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Device Details

Integrated Intravascular Ultrasound and Near-Infrared Spectroscopy (IVUS + NIRS)
VN: Hệ thống siêu âm lòng mạch tích hợp cận hồng ngoại IVUS + NIRS
Risk Class TTBYT Loại B

Registration Details

240000757/PCBB-HCM

000.00.19.H29-240405-0003

Makoto Intravascular Imaging System

TVC-MC10, TVC-MC10i

Company Information

Theo theo phụ lục

Infraredx, Inc.

Technical Details

The Makoto Intravascular Imaging System™ is designed to assess intravascular near-infrared arterial wall imaging in patients undergoing invasive coronary angiography. a) The system is designed to detect the core lipid plaque. b) The system aims to assess the core lipid content of the coronary arteries. c) The system aims to identify patients and plaques at increased risk for significant adverse cardiac events. The system is designed to assess intravascular pathological coronary artery disease. a) Intravascular ultrasound imaging is indicated in patients who are candidates for percutaneous coronary intervention.

Dates and Status

Apr 11, 2024